A retrospective study assessing the effect of ramucirumab on docetaxel efficacy following anti-PD-1/L1 therapy in patients with non-small cell lung cancer
Latest Information Update: 13 Jul 2021
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Jul 2021 New trial record